Key Insights

Highlights

Success Rate

94% trial completion (above average)

Published Results

315 trials with published results (34%)

Research Maturity

749 completed trials (80% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

5.1%

48 terminated out of 938 trials

Success Rate

94.0%

+7.5% vs benchmark

Late-Stage Pipeline

29%

271 trials in Phase 3/4

Results Transparency

42%

315 of 749 completed with results

Key Signals

315 with results94% success48 terminated

Data Visualizations

Phase Distribution

694Total
Not Applicable (201)
Early P 1 (4)
P 1 (100)
P 2 (118)
P 3 (165)
P 4 (106)

Trial Status

Completed749
Unknown77
Terminated48
Recruiting25
Withdrawn20
Not Yet Recruiting10

Trial Success Rate

94.0%

Benchmark: 86.5%

Based on 749 completed trials

Clinical Trials (938)

Showing 20 of 20 trials
NCT05704881RecruitingPrimary

Monitoring of the End-tidal Carbon Dioxide (EtCO2) as a Severity Criterion in COPD Exacerbations

NCT06961214Phase 3RecruitingPrimary

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

NCT05718102Not ApplicableRecruitingPrimary

Pragmatic Trial to Enhance Quality Safety, and Patient Experience in COPD

NCT06712563RecruitingPrimary

Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting

NCT02500693Not ApplicableCompleted

Circulating Tumor Cells in Lung Cancer Screening

NCT05592847Not ApplicableNot Yet Recruiting

A Study of the Effect of a Nurse Navigator Program on High Risk Patients

NCT06477367Not ApplicableCompletedPrimary

Changes in Dyspnea, Activity and Sleep in COPD by Video-Based Breathing Exercises

NCT05265299Phase 3RecruitingPrimary

Trial to Determine Effective Aspirin Dose in COPD

NCT05087641Not ApplicableActive Not Recruiting

A Multicenter, Prospective Trial of the IAB in Adults Suffering From COPD/Emphysema

NCT00683722Phase 2CompletedPrimary

PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT07252908Phase 2RecruitingPrimary

A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder

NCT07415746Not ApplicableNot Yet RecruitingPrimary

Functional Assessment and Pulmonary Rehabilitation: Challenges and Perspectives for Comprehensive Care

NCT05606406Not ApplicableNot Yet RecruitingPrimary

Hypoxia and Heart Rate Variability

NCT07363980Enrolling By Invitation

Coronary Computed Tomography Angiography In Rheumatoid Arthritis Study

NCT03534934Not ApplicableCompletedPrimary

CT-Based Modeling of Bone Micro-Architecture and Fracture-Risk in COPD

NCT05655832Not ApplicableCompletedPrimary

A Study to Investigate the Association of Real-world Sensor-derived Biometric Data With Clinical Parameters and Patient-reported Outcomes for Monitoring Disease Activity in Patients With COPD

NCT03240315Active Not RecruitingPrimary

Personalized Prediction Strategy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease

NCT03404180Phase 4Completed

Peripheral Nerve Blocks for Above-the-knee Amputations

NCT03488628Not ApplicableCompletedPrimary

High-Flow Nasal Oxygen Therapy for Exacerbation of Chronic Pulmonary Obstructive Disease.

NCT04939454Not ApplicableCompletedPrimary

Involvement of Skeletal Muscle Fibrocytes in sarcOpenia in Patients With Chronic ObstRuctive Pulmonary Disease

Scroll to load more

Research Network

Activity Timeline